The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / J&J’s Stelara Shows Promise Against Lupus in Study

J&J’s Stelara Shows Promise Against Lupus in Study

November 7, 2017 • By Bill Berkrot

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Johnson & Johnson’s blockbuster psoriasis drug ustekinumab (Stelara) led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a midstage clinical trial, according to data released on Nov. 4.

You Might Also Like
  • Sifalimumab Shows Some Promise Against Lupus
  • Atacicept Shows Promise in Lupus Treatment Trials
  • Ustekinumab May Be Effective for Lupus

Ustekinumab is already approved for psoriasis, psoriatic arthritis and Crohn’s disease and had third-quarter sales of $1.12 billion.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the trial of 102 patients with active lupus despite being on standard therapy, 60% of those who received Stelara experienced improvement on a scale that measures disease activity after 24 weeks of treatment. That compared with improvement in 31% of patients who received a placebo on top of standard medicines, such as steroids or immunosuppressive drugs, the company reported.

Dr. Ronald van Vollenhoven, the study’s lead investigator, calls the results “pretty exciting and encouraging,” adding that ustekinumab ‘s known safety profile provided added comfort.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

J&J said the results were strong enough to advance ustekinumab into larger phase III testing. There has only been one new drug approved for lupus in the last 50 years, GSK’s Benlysta.

“Any new treatment for lupus is going to be very welcomed by patients and physicians,” says van Vollenhoven, who was scheduled to present the data at the 2017 ACR/ARHP Annual Meeting in San Diego on Nov. 7.1

Lupus is a debilitating and sometimes fatal chronic inflammatory autoimmune disorder that can affect the joints, skin, heart, lungs, kidneys and brain. An estimated 1.5 million Americans and 5 million people worldwide have the disease, which disproportionately affects women.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

On some secondary measures of disease activity, such as Physician Global Assessment, ustekinumab failed to achieve statistical significance over placebo but showed a trend in the right direction, researchers reported. Ustekinumab did lead to significantly fewer disease flare-ups.

Van Vollenhoven said trials for potential new lupus treatments were notoriously difficult because of the way disease activity tends to come and go and because ustekinumab can affect patients differently.

The J&J drug was given intravenously at the start of the trial and then by subcutaneous injections every eight weeks. It works by blocking two proteins believed to play an important role in the immune system’s inflammatory process.

Safety was similar in the two groups with serious adverse events reported in 8.3% of ustekinumab patients and 9.5% of the placebo group.


Reference

  1. van Vollenhoven R, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: Results of a phase 2, randomized placebo-controlled study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: SLE, systemic lupus erythematosus (SLE), ustekinumab

You Might Also Like:
  • Sifalimumab Shows Some Promise Against Lupus
  • Atacicept Shows Promise in Lupus Treatment Trials
  • Ustekinumab May Be Effective for Lupus
  • Mesoblast Cell Treatment Shows Promise in Rheumatoid Arthritis

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.